Plus, news about IN8bio, Sanofi, Vicore Pharma, Cartherics, Zephyrm Bioscience, Tharimmune and Intract Pharma:
Biohaven’s $250M offering: The move comes after Biohaven announced Monday that it started a pivotal Phase 2 study of its oral TRPM3 antagonist for migraines. The company also expects to grant the underwriters another $37.5 million of common shares. — Katherine Lewin
Activist firm grows stake in Galapagos: EcoR1 crossed the 10% ownership threshold tied to voting securities, according to a disclosure on Monday. EcoR1 believes the Dutch biotech is “deeply undervalued” and previously said it would speak to the board and management about a “variety of topics” including board composition. — Max Bayer
IN8bio’s $12.4M raise: The New York gamma-delta T cell therapy biotech priced the private placement a few weeks after announcing plans to prioritize its pipeline and halve its workforce. — Kyle LaHucik
Sanofi invests $10M in Vicore Pharma: The Stockholm-based company is beginning a Phase 2b trial investigating its drug, buloxibutid, in patients with idiopathic pulmonary fibrosis who are either untreated or receiving the current standard of care. — Katherine Lewin
Cartherics raises about $10 million: The money is set to go toward a clinical trial next year for the Melbourne-based company’s preclinical lead cell therapy for ovarian cancer, dubbed CTH-401. According to Cartherics, CTH-401 is the only natural killer cell therapy currently under development that includes a CAR that targets the adenocarcinoma specific antigen called TAG-72. — Katherine Lewin
Zephyrm Bioscience files for IPO in Hong Kong: The seven-year-old startup wants to go public on the Hong Kong Stock Exchange to fund its pipeline of pluripotent stem cell therapies. Its lead therapy is expected to enter Phase 3 next year for two indications: acute exacerbation of interstitial lung disease, and acute graft versus host disease. — Kyle LaHucik
Tharimmune, Intract Pharma to merge: The clinical-stage I&I biotech wants to combine with Intract, which makes a delivery system for oral biologics. The merger is slated to close in the first quarter of 2025, and Intract shareholders will own 49% of the combined company. — Kyle LaHucik